OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Glucagon-like peptide 1 (GLP-1) receptor agonists, as well as dipeptidyl peptidase-4 inhibitors, have recently been widely used as therapeutics of type 2 diabetes [1]. According to the accumulation of clinical experience, cardiovascular protective effects of GLP-1 receptor agonists have been focused [2,3]. Although these effects may partly be due to their indirect glucose-lowering and weight-losing effects [4], recent evidence has indicated their direct effects on endothelium.
